[Event Report] Non-partisan Diet Member Briefing – Creating Pull Incentives to Spur the Development of Antimicrobials (April 22, 2021)
date : 4/22/2021
Tags: AMR, Diet Member Briefing
AMR Alliance Japan held a Diet Member briefing about “Creating Pull Incentives to Spur the Development of Antimicrobials.”
Despite the growing threat of antimicrobials resistance (AMR) – the natural process by which the germs that cause infectious disease grow immune to existing antimicrobials over time – the world has seen a decline in the development of novel antimicrobials since the 1980s.
This problem has arisen from a market failure. It can take 10-15 years and over US$1 billion to develop an antimicrobial. Once an antimicrobial is approved for use, it is important to take care not to overuse it. As a result, new antimicrobials typically see low sales, and companies face problems in covering post-approval costs. This issue has led to the collapse of multiple companies that developed antimicrobials in recent years.
AMR Alliance Japan (Secretariat: Health and Global Policy Institute) has been serving as secretariat for the Nikkei FT Communicable Diseases Conference Asia Africa Asia Medical Innovation Consortium (AMIC) AMR Consortium. The AMR Consortium has developed recommendations on “pull incentives” for antimicrobial development that could solve the above issues.
For this Diet Briefing, HGPI invited two speakers to discuss the realization of pull incentives in Japan. Afterward, there was a question and answer session with the Diet Members.
Recommendations on Pull Incentives for AMR in Japan Executive Summary
■Program
Explanatory Introduction
Matt McEnany (Senior Manager, HGPI)
Presentation 1
“The Threat of AMR and the Need for Countermeasures”
Dr. Norio Ohmagari (Director of the AMR Clinical Reference Center and Director of the Disease Control and Prevention Center of the National of Center for Global Health and Medicine (NCGM))
Presentation 2
“Recommendations from the AMR Consortium: Realizing a Pull Incentive”
Dr. Kazumasa Oguro (Professor, Faculty of Economics, Hosei University)
【About AMR Alliance Japan】
AMR Alliance Japan was established in November 2018 as multi-stakeholder, collaborative organization dedicated to the improvement of public health through the promotion of AMR countermeasures. As of June 2021, its members include, in alphabetical order: The Japan Medical Association; The Japan Pharmaceutical Association; The Japan Pharmaceutical Manufacturers Association; The Japan Society of Hospital Pharmacists; The Japanese Association for Infectious Diseases; The Japanese Society for Chemotherapy; The Japanese Society for Clinical Microbiology; The Japanese Society for Medical Mycology; The Japanese Society for Pediatric Infectious Diseases; The Japanese Society of Infection Prevention and Control; The Japanese Society of Pharmaceutical Health Care and Sciences; The Japanese Society of Therapeutic Drug Monitoring; MSD K.K.; Shionogi & Co., Ltd.; Nippon Becton Dickinson Co., Ltd.; Pfizer Inc.; The Pharmaceutical Society of Japan. The Health and Global Policy Institute serves as the Secretariat of AMR Alliance Japan.
日本語
Top Research & Recommendations Posts
- [Report and Recommendations] Discussion Points in Healthcare DX Project Expert Panel Meeting (April 2, 2024)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Event Report] Planetary Health Expert Meeting Aiming for Sustainable Healthcare: Learning from the Impact of Environmental Pollution and Medical Waste During the Pandemic (February 16, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Announcement] HGPI Joins Global Climate and Health Alliance (March 23, 2024)
- [Policy Recommendations] Kidney Disease Control Promotion Project 2023 “Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration” Policy Recommendations, a Collection of Good Practices of Chronic Kidney Disease (CKD) and Control Measures in Local Governments (February 14, 2024)
- [Announcement] HGPI Joins Alliance for Transformative Action on Climate and Health (April 22, 2024)
Featured Posts
-
2024-04-22
[Registration Open] (Hybrid Format) Intractable Disease Day Symposium: Future Measures for Intractable Diseases from the Perspectives of Patients and Citizens (May, 23 2024)
-
2024-04-23
[Registration Open] The 125th HGPI Seminar: Progress and Prospects for Domestic Measures on Health Problems Caused by Alcohol (May 24 , 2024)
-
2024-04-26
[Policy Recommendations] Obesity Control Promotion Project 2023 “The Next Steps for Engaging and Cooperating with Patients, Citizens, and Communities for Implements of Obesity Control Measurements” (April 8, 2024)
-
2024-05-01
[Registration Open] The Global Health Education Program (G-HEP) 2024 (May 1, 2024)
-
2024-05-02
[Announcement] Recruitment of the Health Policy Academy the 13th Session